Ipsen Sa Adr (OTCMKTS:IPSEY) was upgraded by equities researchers at Societe Generale from a “hold” rating to a “buy” rating in a research report issued on Tuesday.

Separately, Zacks Investment Research upgraded shares of Ipsen Sa Adr from a “hold” rating to a “strong-buy” rating and set a $38.00 price target for the company in a report on Monday, July 31st.

Shares of Ipsen Sa Adr (OTCMKTS IPSEY) traded up 4.42% during midday trading on Tuesday, hitting $34.50. 5,500 shares of the stock traded hands. The firm’s 50-day moving average is $32.95 and its 200 day moving average is $30.23. The company has a market capitalization of $11.36 billion and a price-to-earnings ratio of 43.67. Ipsen Sa Adr has a 52 week low of $16.24 and a 52 week high of $35.71.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/19/ipsen-sa-adr-ipsey-raised-to-buy-at-societe-generale.html.

Ipsen Sa Adr Company Profile

Ipsen SA operates as a pharmaceutical company worldwide. It operates in two segments, Primary Care and Specialty Care. The company offers drugs in urology – oncology, endocrinology, neurology, gastroenterology, cognitive disorders, rheumatology, and cardiovascular areas. Its products include Decapeptyl, a synthetic hormone made of triptorelin and decapeptide analog of gonadotrophin releasing hormone, for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; Hexvix, a photosensitizing agent, for detection and resection of non invasive bladder cancer; and Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors.

Receive News & Stock Ratings for Ipsen Sa Adr Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen Sa Adr and related stocks with our FREE daily email newsletter.